NZ525885A - Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities - Google Patents

Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities

Info

Publication number
NZ525885A
NZ525885A NZ525885A NZ52588501A NZ525885A NZ 525885 A NZ525885 A NZ 525885A NZ 525885 A NZ525885 A NZ 525885A NZ 52588501 A NZ52588501 A NZ 52588501A NZ 525885 A NZ525885 A NZ 525885A
Authority
NZ
New Zealand
Prior art keywords
compound
nov
iponz
pharmaceutical composition
receptor
Prior art date
Application number
NZ525885A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Bryan Mckibben
David J Witter
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NZ525885A publication Critical patent/NZ525885A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NZ525885A 2000-12-01 2001-11-30 Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities NZ525885A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (fr) 2000-12-01 2001-11-30 Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations

Publications (1)

Publication Number Publication Date
NZ525885A true NZ525885A (en) 2005-01-28

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ525885A NZ525885A (en) 2000-12-01 2001-11-30 Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities

Country Status (20)

Country Link
EP (1) EP1347980A4 (fr)
JP (1) JP4579497B2 (fr)
CN (1) CN1263757C (fr)
AP (1) AP1893A (fr)
AU (1) AU2002248151B2 (fr)
BR (1) BR0115847A (fr)
CA (1) CA2430577A1 (fr)
CZ (1) CZ20031831A3 (fr)
EA (1) EA007254B1 (fr)
HU (1) HUP0400692A3 (fr)
IL (1) IL155962A0 (fr)
ME (1) MEP35308A (fr)
MX (1) MXPA03004717A (fr)
NO (1) NO327207B1 (fr)
NZ (1) NZ525885A (fr)
OA (1) OA13295A (fr)
PL (1) PL363245A1 (fr)
WO (1) WO2002057267A1 (fr)
YU (1) YU42703A (fr)
ZA (1) ZA200303729B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
CZ302486B6 (cs) 1998-06-02 2011-06-15 Osi Pharmaceuticals, Inc. N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
EP1450811B1 (fr) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Composés specifiques aux recepteurs A1 et A3 de l'adenosine et leur utilisations
CA2469316A1 (fr) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Composes a base de pyrimidine utiles en tant qu'inhibiteurs des gsk-3
EA011809B1 (ru) 2001-12-20 2009-06-30 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CA2502429A1 (fr) * 2002-10-31 2004-05-21 Amgen Inc. Agents anti-inflammatoires
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP3421471B1 (fr) 2006-04-25 2021-05-26 Astex Therapeutics Limited Dérivés de purine et de déazapurine comme composés pharmaceutiques
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
WO2009047563A1 (fr) 2007-10-11 2009-04-16 Astrazeneca Ab Dérivés pyrrolo[2,3-d]pyrimidine comme inhibiteurs de la protéine kinase b
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2247596A2 (fr) 2008-01-11 2010-11-10 Natco Pharma Limited Nouveaux derives de pyrazolo [3,4 -d] pyrimidine en tant qu'agents anticancereux
SI2694056T1 (sl) 2011-04-01 2019-12-31 Astrazeneca Ab Terapevtsko zdravljenje
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104350056A (zh) * 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
CA2915561C (fr) 2013-06-21 2020-09-22 Zenith Epigenetics Corp. Nouveaux composes bicycliques substitues utilises comme inhibiteurs de bromodomaines
EA035601B1 (ru) 2013-06-21 2020-07-14 Зенит Эпидженетикс Лтд. Бициклические ингибиторы бромодомена
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
EP3227281A4 (fr) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Pyridinones substituées utilisées comme inhibiteurs de bromodomaines
CA2966303A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Pyridines substituees comme inhibiteurs de bromodomaine
CA2966449A1 (fr) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Heterocycles substitues a titre d'inhibiteurs de bromodomaines
EP3233846A4 (fr) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibiteurs de bromodomaines
CN108349977B (zh) * 2015-01-20 2021-05-25 无锡福祈制药有限公司 Jak抑制剂
KR102006684B1 (ko) 2015-04-29 2019-08-02 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
CA2983481C (fr) 2015-05-29 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteur de la janus kinase
CN105771672B (zh) * 2016-04-18 2018-03-02 天津工业大学 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
CN108570054B (zh) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
KR20210033444A (ko) * 2018-06-04 2021-03-26 엑스사이언티아 엘티디 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895961B2 (ja) * 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
CZ302486B6 (cs) * 1998-06-02 2011-06-15 Osi Pharmaceuticals, Inc. N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
KR100840727B1 (ko) * 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
EP1450811B1 (fr) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Composés specifiques aux recepteurs A1 et A3 de l'adenosine et leur utilisations

Also Published As

Publication number Publication date
JP4579497B2 (ja) 2010-11-10
EP1347980A4 (fr) 2005-02-09
ZA200303729B (en) 2004-05-14
MEP35308A (en) 2011-02-10
NO327207B1 (no) 2009-05-11
YU42703A (sh) 2006-03-03
OA13295A (en) 2007-04-13
CN1489590A (zh) 2004-04-14
CZ20031831A3 (cs) 2004-05-12
NO20032482D0 (no) 2003-06-02
MXPA03004717A (es) 2004-06-30
AU2002248151B2 (en) 2008-02-21
CA2430577A1 (fr) 2002-07-25
BR0115847A (pt) 2004-02-25
NO20032482L (no) 2003-07-28
HUP0400692A3 (en) 2007-09-28
CN1263757C (zh) 2006-07-12
IL155962A0 (en) 2003-12-23
EA007254B1 (ru) 2006-08-25
EA200300628A1 (ru) 2003-12-25
AP2003002807A0 (en) 2003-06-30
EP1347980A1 (fr) 2003-10-01
WO2002057267A1 (fr) 2002-07-25
AP1893A (en) 2008-09-23
PL363245A1 (en) 2004-11-15
JP2004517896A (ja) 2004-06-17
HUP0400692A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
AU2002248151B2 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
US6673802B2 (en) Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) Compounds specific to adenosine A1 receptors and uses thereof
AU763658B2 (en) Pyrrolo(2,3d)pyrimidine compositions and their use
US6680322B2 (en) Compounds specific to adenosine A1 receptors and uses thereof
AU784878B2 (en) Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
US20020094974A1 (en) Compounds specific to adenosine A3 receptor and uses thereof
AU2002248151A1 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
US6664252B2 (en) 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6686366B1 (en) Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) Compounds specific to adenosine A1 receptor and uses thereof
KR100897430B1 (ko) 아데노신 ａ₁, ａ₂ａ 및 ａ₃ 수용체에 특이적인 화합물및 그의 용도

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)